MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
16.06
+0.23
+1.45%
Opening 11:41 12/19 EST
OPEN
15.77
PREV CLOSE
15.83
HIGH
16.16
LOW
15.51
VOLUME
310.75K
TURNOVER
--
52 WEEK HIGH
19.17
52 WEEK LOW
3.500
MARKET CAP
1.05B
P/E (TTM)
64.11
1D
5D
1M
3M
1Y
5Y
1D
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Encouraging Phase 1/2 Prostate Cancer Trial Results
Simply Wall St · 9h ago
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE)
TipRanks · 2d ago
Monte Rosa Therapeutics: Promising Progress with MRT-2359 in Advanced Prostate Cancer
TipRanks · 2d ago
Is MRT-2359 Prostate Cancer Data Update Altering The Investment Case For Monte Rosa Therapeutics (GLUE)?
Simply Wall St · 2d ago
Why Is Monte Rosa Stock Trading Higher Today?
Benzinga · 2d ago
Monte Rosa Therapeutics Rises on Positive Interim Data for Prostate Cancer Treatment
Dow Jones · 3d ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 3d ago
Monte Rosa Therapeutics Price Target Raised to $22.00/Share From $13.00 by Wells Fargo
Dow Jones · 3d ago
More
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Webull offers Monte Rosa Therapeutics Inc stock information, including NASDAQ: GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.